| EPA088 | Adverse events following COVID-19 vaccination among people with HIV: review of available vaccine safety literature | E-poster | SARS-Cov2 vaccines |
| EPA089 | Potent cytotoxic activity against SARS-CoV-2 of CD8+ T cells from individuals with HIV who received complete schedule of COVID-19 vaccines | E-poster | SARS-Cov2 vaccines |
| EPA090 | Factors associated with SARS-CoV2 vaccination acceptance in people with HIV participating in the SCAPE-HIV study | E-poster | SARS-Cov2 vaccines |
| EPA091 | Immunogenicity of mRNA-1273 COVID-19 vaccination in PLWH after inadequate primary vaccination response | E-poster | SARS-Cov2 vaccines |
| EPA092 | SARS-CoV-2 Omicron Spike recognition by plasma fromindividuals receiving BNT162b2 mRNA vaccination with a 16-weeks interval between doses | E-poster | SARS-Cov2 vaccines |
| EPA093 | Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected Individuals not responding to the Ad26.COV2.S vaccine | E-poster | SARS-Cov2 vaccines |
| EPA094 | Characterization of serum and mucosal SARS-CoV-2-antibodies in HIV-1 infected subjects after BNT162b2 mRNA vaccination or SARS-CoV-2 infection | E-poster | SARS-Cov2 vaccines |
| PEMOA33 | Serological responses to SARS-CoV2 vaccination in people with HIV: the SCAPE-HIV study | Poster exhibition | SARS-Cov2 vaccines |
| PEMOA35 | Side-by-side comparison of SARS-CoV-2 neutralizing antibody responses after various COVID-19 vaccine regimens | Poster exhibition | SARS-Cov2 vaccines |
| PEMOA36 | Immunogenicity of the BNT 162b2 mRNA vaccine against COVID-19 variants in people living with HIV on antiretroviral therapy in Malaysia | Poster exhibition | SARS-Cov2 vaccines |